(A) Schematic map showing SETD2 mutations in LB996 and A498 cell lines. The locations of SET domain and SRI domain were mapped according to Uniprot.org. The amino acid changes are quoted from published literature but adjusted to the updated sequence of SETD2 (in the new version, 503 amino acids were added to the N-terminus of the protein). A498 expresses a nonfunctional SETD2 protein while LB996 does not express SETD2 protein. (B) Analysis of potential off-target SETD2-CRISPR sites. Potential off-target sites of the gRNA was predicted using the MIT CRISPR design tool (http://crispr.mit.edu/). The top three predicted offtarget sites were chosen. Genomic DNA was extracted from U2OS parental and U2OS CRISPR SETD2-knockout cells. PCR was performed on genomic DNA with primers located approximately 500 bp on each side of the predicted off-target site. The PCR product was cleaned by Qiagen spin column and sequenced by Sanger sequencing. The sequences were aligned using BioEdit ClustalW multiple sequence alignment tool. (C) Validation of CRISPR SETD2-knockout. To study the mutation patterns on the two alleles in the CRISPR knockout cell, genomic DNA was extracted from U2OS parental and U2OS CRISPR SETD2-knockout cells. Genomic PCR was performed as in (B) with primers 500 bp from the target site, and the PCR products were subcloned into a TOPO vector, transformed into competent cells, and 6 clones were sequenced separately by Sanger sequencing. The sequences were aligned using BioEdit ClustalW multiple sequence alignment tool and the amino acid translation was cross-checked with the amino acid sequence from CCDS report. (D) Clonogenic survival curves of U2OS parental and U2OS CRISPR SETD2-knockout cells after exposure to WEE1 inhibitor AZD1775 (4 days) at indicated concentrations. Colonies were allowed to form for 14 days. Data are presented as mean ± SEM, n = 3 independent experiments. (E) U2OS or U2OS CRISPR SETD2-knockout cells were transfected with either control siRNA (siNT) or WEE1 siRNA (siWEE1) for 5 days, viability was measured by Resazurin. Data are presented as mean ± SEM, n = 3 independent experiments. ***p < 0.001. Western blot showing WEE1 protein levels 48 hr after siRNA transfection. (F) U2OS CRISPR SETD2-knockout cells were transfected with siNT or siWEE1 for 48 hr before treatment with either DMSO or AZD1775 (400 nM). Viability was measured by Resazurin 3 days after inhibitor treatment. Data are presented as mean ± SEM, n = 3 independent experiments. n.s. not significant. (G) Western blot analysis of pCDK1 (Y15) and pan-CDK substrate levels in U2OS and U2OS CRISPR SETD2-knockout cells. Cells were treated with indicated concentrations of AZD1775 and harvested at the indicated times. Lysis buffer contained protease inhibitor and phosphatase inhibitor cocktail. Western blots were performed using anti-phospho-CDK1 (Tyr 15) or antiphospho-pan-CDK antibodies. Tubulin was used as loading control. (H) Western blot analysis of pCDK1 T14 and Y15 levels in U2OS and U2OS CRISPR SETD2-knockout cells. Cells were treated with indicated concentrations of AZD1775 and harvested after 24 hr. Western blots were performed using antibodies against phospho-CDK1 (Thr 14) (substrate of MYT1) and phospho-CDK1 (Tyr 15) (substrate of WEE1). Tubulin was used as loading control. Time after AZD1775 (hr) % pH3 (S10) hr after transfection, cells were treated with AZD1775 and viability was measured by Resazurin after 3 days. (R) qRT-PCR analysis of SETD2 and BRCA2 mRNA levels in (Q). All data in Figure S2 are presented as mean ± SEM, n = 3 independent experiments. Unpaired, twotailed t-test was performed, ***p < 0.001, **p < 0.01, *p < 0.05, n.s. not significant. ChIP-qPCR analysis of the enrichment of H3K36me3 across the gene body of RRM2, using primers described in (F) . (H) ChIP-qPCR analysis of the enrichment of RNA polymerase 2 (Pol2) across the gene body of RRM2, using primers described in (F) . (I) ChIP-qPCR analysis of enrichment of phospho-Pol2 at serine 5 (pSer5-pol2) at primer positions 1-3 of the RRM2 gene, using primers described in (F) . (J) ChIP-qPCR analysis of enrichment of phospho-Pol2 at serine 2 (pSer2-pol2) at primer positions 3-5 of the RRM2 gene, using primers described in (F) . (pSer5-pol2 is usually increased at the 5' end of the transcribed gene while pSer2-pol2 increases towards the 3' end of the gene.) U2OS parental cells or U2OS SETD2 CRISPR knockout cells were harvested 24 hr after seeding. (K) Relative viability of U2OS CRISPR SETD2-knockout cells after transient transfection with control plasmid, plasmid containing SETD2 cDNA or plasmid containing RRM2 (T33A) cDNA. 48 hr after transfection, cells were treated with DMSO or AZD1775 and cell viability measured by Resazurin after 3 days. Viability was normalised to DMSO treatment in each condition. (L) U2OS CRISPR SETD2-knockout cells were transiently transfected as in (K) . Percentage of apoptotic cells was measured 48 hr after AZD1775 treatment.
All data in Figure S3 are presented as mean ± SEM, n = 3 independent experiments. Unpaired, twotailed t-test was performed, ***p < 0.001, **p < 0.01, *p < 0.05.
Non-replicating S 2% 40% 5% 21% Viability relative to DMSO treatment (Q) Measurement of dNTP levels in U2OS cells stably expressing degradation-resistant RRM2 (T33A) after transfection with either non-targeting siRNA (siNT) or SETD2 siRNA (siSETD2) for 48 hr, and DMSO or AZD1775 (200 nM) treatment for 24 hr. Data are normalized to the control (siNT+DMSO).
(R) Viability curves of U2OS CRISPR SETD2-knockout cells transfected with either non-targeting siRNA (siNT) or CDT1 siRNA (siCDT1) (48 hr) and exposed to AZD1775 (5 days). Western blots showing the knockdown of CDT1 protein.
(S) FACS analysis of BrdU incorporation in U2OS CRISPR SETD2-knockout cells transfected with either non-targeting siRNA (siNT) or CDC6 siRNA (siCDC6) (48 hr) and exposed to DMSO or AZD1775 (48 hr). The percentage of non-replicating S-phase population are shown.
(T) Viability curves of U2OS and U2OS CRISPR SETD2-knockout cells after treatment with indicated concentrations of hydroxyurea (HU) (5 days).
(U) Viability curves of U2OS and U2OS CRISPR SETD2-knockout cells after treatment with indicated concentrations of gemcitabine (5 days).
All data in Figure S4 are presented as mean ± SEM, n = 3 independent experiments, p values are calculated by unpaired, two-tailed t-test or column statistics (one sample t-test) wherever appropriate. ***p < 0.001, **p < 0.01, *p < 0.05, n.s. not significant. Mean body weight of tumor-bearing mice treated with either vehicle or AZD1775 as described in Figure 5A . Data are presented as mean ± SEM, n = 7 mice.
Supplemental Experimental Procedures
Cell culture U2OS (human osteosarcoma), A498 (human renal cell carcinoma) and RCC4 (human renal cell carcinoma) cell lines were cultured at 37 °C with 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% v/v fetal bovine serum (FBS) and penicillin (100 units/ml) / streptomycin (0.1 mg/ml). LB996
(human renal cell carcinoma) was obtained from Benoît Van den Eynde and was cultured in IMDM supplemented with 10% FBS, penicillin/streptomycin and G5 supplement (Invitrogen). All cell lines were routinely tested for mycoplasma and found to be negative.
Genomic validation of CRISPR SETD2 knockout cells
The CRISPR knockout cells were validated at the DNA level by genomic PCR and Sanger sequencing. Genomic DNA was extracted from U2OS parental and U2OS CRISPR SETD2-knockout cells. PCR was performed on the genomic DNA with primers located approximately 500 bp on each side of the target site. The PCR product was cleaned by Qiagen spin column and sequenced by Sanger sequencing.
The sequences from U2OS parental, U2OS CRISPR, NCBI reference genome and target sequence were aligned using BioEdit ClustalW multiple sequence alignment tool. The amino acid translation was cross-checked with the amino acid sequence from the CCDS report.
Potential off-target sites of the gRNA was predicted using the MIT CRISPR design tool (http://crispr.mit.edu/). The top three predicted off-target sites were chosen and primers were designed to be approximately 500 bp on each side of the 
Resazurin assay for cell viability
Equal numbers of cells were seeded in a 96-well plate 24 hr before inhibitor treatment. DMSO (solvent for the inhibitors) was used as a negative control. The inhibitor was washed off after 3 days. 5 days after addition of inhibitors, the media were removed and fresh media containing Resazurin were added to each well.
Resazurin is a nonfluorescent dye, which can be converted (by redox reaction) to a red fluorescent resorufin by living cells. The fluorescent signal is proportional to the number of living cells, and was measured by a fluorescence plate reader (BMG Labtech).
Assay for apoptosis
Equal numbers of cells were seeded in a 96-well plate 24 hr prior to inhibitor treatment. 48 hr after addition of inhibitors, Hoechst was added to the media.
Hoechst stains the DNA, and the nuclei of apoptotic cells appear condensed and bright. Images were taken using Incell Analyzer (GE Healthcare) and the number apoptotic cells were counted using Incell Analysis software (GE Healthcare), and presented as a percentage of total number of cells.
Clonogenic survival assay
400 cells were plated per well in 6-well plates. 4 hr after plating, cells were treated with desired inhibitors at indicated concentrations. The inhibitors were washed off after 4 days and colonies were fixed and stained after 14 days. Plating efficiency (PE) and surviving fraction (SF) were calculated according to Nature
Protocol.
Gene complementation
For expression of wild-type SETD2 in SETD2-deficient cells (A498), wild-type full length SETD2 cDNA was purchased from Source Bioscience and inserted into pcDNA6.2-DEST mammalian expression plasmid (Invitrogen). After verification by sequencing, the plasmid was transfected into A498 cells by electroporation and an empty vector was used as control. Stable integrations were selected by Blasticidin.
Generation of Doxycycline inducible KDM4A U2OS cells and stable H3.3K36M
U2OS cells are described previously (Pfister et al., 2014) , and are cultured in complete DMEM medium with appropriate selection. 
Cell cycle analysis by BrdU incorporation
Cells were incubated in media containing 20 µM BrdU for 20 min at 37 °C and protected from light. Cells were collected by trypsinisation and fixed in ice-cold 70%
